Advertisement

Annals of Hematology

, Volume 98, Issue 10, pp 2463–2465 | Cite as

Multiple myeloma with IGH-FGFR3 rearrangement progressing as testicular plasmacytoma during carfilzomib treatment

  • Nobuhiko Nakamura
  • Dai MaruyamaEmail author
  • Akiko Miyagi Maeshima
  • Yo Saito
  • Takahiro Fujino
  • Yuta Ito
  • Shunsuke Hatta
  • Shinichi Makita
  • Suguru Fukuhara
  • Wataru Munakata
  • Tatsuya Suzuki
  • Hiroyuki Fujimoto
  • Koji Izutsu
Letter to the Editor
  • 80 Downloads

Dear Editor,

Multiple myeloma (MM) is a heterogeneous hematological malignancy with the clonal proliferation of plasma cells. Although MM remains incurable, treatment strategies have been improved by developing new agents and the overall survival of MM patients has significantly increased in the last decades [1]. Extramedullary spread of MM may occur either at diagnosis or during the disease course, and testis involvement is rare. We report an MM patient with IGH-FGFR3 rearrangement progressing as a testicular plasmacytoma during carfilzomib (CFZ) treatment.

A 72-year-old man was diagnosed with MM with IGH-FGFR3 rearrangement (IgG-λ, stage 2 according to the International Staging System [ 2]) 8 years ago. He received 3 cycles of bortezomib and dexamethasone induction therapy, and high-dose melphalan followed by autologous stem cell transplantation. He achieved very good partial response (VGPR) and was followed-up without any treatment. Four years later, he had significant paraprotein...

Notes

Compliance with ethical standards

Conflict of interest

Dai Maruyama has received honoraria and research funding from Janssen, Celgene, Ono, and Bristol-Myers Squibb Japan.

Informed consent

Informed consent to publish case details was obtained from the patient.

References

  1. 1.
    Costa LJ, Brill IK, Omel J, Godby K, Kumar SK, Brown EE (2017) Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Adv 1:282–287.  https://doi.org/10.1182/bloodadvances.2016002493 CrossRefGoogle Scholar
  2. 2.
    Sonneveld P, Westin J, Shimizu K, Morgan G, Greipp PR, Durie BGM, Ludwig H, Avet-Loiseau H, Kyle RA, Powles R, Shustik C, Child JA, Bladé J, Turesson I, Lahuerta JJ, Barlogie B, Miguel JS, Boccadoro M, Crowley JJ, Tosi P (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412–3420.  https://doi.org/10.1200/jco.2005.04.242 CrossRefGoogle Scholar
  3. 3.
    Alexiou C, Kau RJ, Dietzfelbinger H, Kremer M, Spiess JC, Schratzenstaller B, Arnold W (1999) Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer 85:2305–2314CrossRefGoogle Scholar
  4. 4.
    Lazzarino M, Pica G, Varettoni M, Mangiacavalli S, Corso A, Pascutto C (2009) Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 21:325–330.  https://doi.org/10.1093/annonc/mdp329 Google Scholar
  5. 5.
    Rosenberg S, Shapur N, Gofrit O, Or R (2010) Plasmacytoma of the testis in a patient with previous multiple myeloma: is the testis a sanctuary site? J Clin Oncol 28:e456–e458.  https://doi.org/10.1200/jco.2009.27.6519 CrossRefGoogle Scholar
  6. 6.
    Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, Klasa R, Ozsahin M, Mead GM, Gianni MA, Cortelazzo S, Ferreri AJM, Ambrosetti A, Martelli M, Thiéblemont C, Moreno HG, Pinotti G, Martinelli G, Mozzana R, Grisanti S, Provencio M, Balzarotti M, Laveder F, Oltean G, Callea V, Roy P, Cavalli F, Gospodarowicz MK (2003) Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the international extranodal lymphoma study group. J Clin Oncol 21:20–27.  https://doi.org/10.1200/JCO.2003.11.141 CrossRefGoogle Scholar
  7. 7.
    Sonneveld P, Lonial S, Usmani S, Siegel D, Anderson KC, Van De Donk NWCJ, Einsele H, Blad J, Palumbo A, Orlowski R (2017) Perspectives treatment of multiple myeloma with high-risk cytogenetics : a consensus of the international myeloma working group. Blood 127:2955–2963.  https://doi.org/10.1182/blood-2016-01-631200.BLOOD CrossRefGoogle Scholar
  8. 8.
    Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ, Belch AR, Pilarski LM (2003) In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 101:1520–1529.  https://doi.org/10.1182/blood-2002-06-1675 CrossRefGoogle Scholar
  9. 9.
    Avet-Loiseau H, Leleu X, Roussel M, Moreau P, Guerin-Charbonnel C, Caillot D, Marit G, Benboubker L, Voillat L, Mathiot C, Kolb B, Macro M, Campion L, Wetterwald M, Stoppa A-M, Hulin C, Facon T, Attal M, Minvielle S, Harousseau J-L (2010) Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 28:4630–4634.  https://doi.org/10.1200/JCO.2010.28.3945 CrossRefGoogle Scholar
  10. 10.
    Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Špička I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos M-V, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P (2016) Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood 128:1174–1180.  https://doi.org/10.1182/blood-2016-03-707596 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Nobuhiko Nakamura
    • 1
  • Dai Maruyama
    • 1
    Email author
  • Akiko Miyagi Maeshima
    • 2
  • Yo Saito
    • 1
  • Takahiro Fujino
    • 1
  • Yuta Ito
    • 1
  • Shunsuke Hatta
    • 1
  • Shinichi Makita
    • 1
  • Suguru Fukuhara
    • 1
  • Wataru Munakata
    • 1
  • Tatsuya Suzuki
    • 1
  • Hiroyuki Fujimoto
    • 3
  • Koji Izutsu
    • 1
  1. 1.Department of HematologyNational Cancer Center HospitalTokyoJapan
  2. 2.Department of Pathology and Clinical LaboratoryNational Cancer Center HospitalTokyoJapan
  3. 3.Department of UrologyNational Cancer Center HospitalTokyoJapan

Personalised recommendations